125 related articles for article (PubMed ID: 31239190)
1. [Post chemoterapy febrile neutropenia. Length of stay and experience in our population].
Pérez-Heras Í; Raynero-Mellado RC; Díaz-Merchán R; Domínguez-Pinilla N
An Pediatr (Engl Ed); 2020 Mar; 92(3):141-146. PubMed ID: 31239190
[TBL] [Abstract][Full Text] [Related]
2. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
Nguyen M; Jacobson T; Torres J; Wann A
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593
[TBL] [Abstract][Full Text] [Related]
3. Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.
Daniels LM; Durani U; Barreto JN; O'Horo JC; Siddiqui MA; Park JG; Tosh PK
Support Care Cancer; 2019 Nov; 27(11):4171-4177. PubMed ID: 30805726
[TBL] [Abstract][Full Text] [Related]
4. Obesity is not strongly associated with increased risk for febrile neutropenia during levofloxacin prophylaxis in patients with hematological malignancies receiving intermediate-risk myelosuppressive chemotherapy.
Kurtti A; Fritz K; Elofson-Disney K; Benefield R
J Oncol Pharm Pract; 2020 Sep; 26(6):1301-1305. PubMed ID: 31810423
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Microbiologically-documented Infections, Mortality and Prolonged Hospital Stay in Children with Febrile Neutropenia.
Das A; Trehan A; Bansal D
Indian Pediatr; 2018 Oct; 55(10):859-864. PubMed ID: 29941699
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with hospital length of stay among cancer patients with febrile neutropenia.
Rosa RG; Goldani LZ
PLoS One; 2014; 9(10):e108969. PubMed ID: 25285790
[TBL] [Abstract][Full Text] [Related]
7. [Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database].
Freyer G; Scotte F; Borget I; Bruyas A; Vainchtock A; Chouaid C
Bull Cancer; 2016 Jun; 103(6):552-60. PubMed ID: 27233367
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of procalcitonin, C-reactive protein, presepsin, and soluble-triggering receptor expressed on myeloid cell levels in bloodstream infections in pediatric patients with febrile neutropenia.
Özdemir ZC; Düzenli-Kar Y; Canik A; Küskü-Kiraz Z; Özen H; Bör Ö
Turk J Pediatr; 2019; 61(3):359-367. PubMed ID: 31916713
[TBL] [Abstract][Full Text] [Related]
9. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.
Wang L; Barron R; Baser O; Langeberg WJ; Dale DC
Value Health; 2014 Sep; 17(6):739-43. PubMed ID: 25236998
[TBL] [Abstract][Full Text] [Related]
10. Decision-tree derivation and external validation of a new clinical decision rule (DISCERN-FN) to predict the risk of severe infection during febrile neutropenia in children treated for cancer.
Delebarre M; Gonzales F; Behal H; Tiphaine A; Sudour-Bonnange H; Lutun A; Abbou S; Pertuisel S; Thouvenin-Doulet S; Pellier I; Mansuy L; Piguet C; Paillard C; Blanc L; Thebaud E; Plantaz D; Blouin P; Schneider P; Guillaumat C; Simon P; Domenech C; Pacquement H; Le Meignen M; Pluchart C; Vérite C; Plat G; Martinot A; Duhamel A; Dubos F
Lancet Child Adolesc Health; 2022 Apr; 6(4):260-268. PubMed ID: 34871572
[TBL] [Abstract][Full Text] [Related]
11. The role of procalcitonin in identifying high-risk cancer patients with febrile neutropenia: A useful alternative to the multinational association for supportive care in cancer score.
Chaftari P; Chaftari AM; Hachem R; Yeung SJ; Dagher H; Jiang Y; Malek AE; Dailey Garnes N; Mulanovich VE; Raad I
Cancer Med; 2021 Dec; 10(23):8475-8482. PubMed ID: 34725958
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of sTREM-1, IL-8, PCT, and CRP in febrile neutropenia after autologous stem cell transplantation.
Michel CS; Teschner D; Wagner EM; Theobald M; Radsak MP
Ann Hematol; 2017 Dec; 96(12):2095-2101. PubMed ID: 28920169
[TBL] [Abstract][Full Text] [Related]
13. Comparison of CRP and procalcitonin for etiological diagnosis of fever during febrile neutropenia in hematology patients- an experience from a tertiary care center in Northern India.
Halder R; Seth T; Chaturvedi PK; Mishra P; Mahapatra M; Pati HP; Tyagi S; Saxena R
Blood Cells Mol Dis; 2020 Sep; 84():102445. PubMed ID: 32480243
[TBL] [Abstract][Full Text] [Related]
14. Prospective cohort study of procalcitonin levels in children with cancer presenting with febrile neutropenia.
Hemming V; Jakes AD; Shenton G; Phillips B
BMC Pediatr; 2017 Jan; 17(1):2. PubMed ID: 28056911
[TBL] [Abstract][Full Text] [Related]
15. A retrospective analysis of clinical acuity markers on hospital length of stay in patients with febrile neutropenia.
Johannesmeyer HJ; Seifert CF
J Oncol Pharm Pract; 2019 Apr; 25(3):535-543. PubMed ID: 29207937
[TBL] [Abstract][Full Text] [Related]
16. Procalcitonin adds to diagnosis, but does not reduce initial antibiotics in febrile neutropenic children.
Lodahl D; Schrøder H
Dan Med Bull; 2011 Mar; 58(3):A4233. PubMed ID: 21371399
[TBL] [Abstract][Full Text] [Related]
17. Adrenomedullin--A New Marker in Febrile Neutropenia: Comparison With CRP and Procalcitonin.
Demirkaya M; Tugcu D; Akcay A; Aydogan G; Akıcı F; Salcioglu Z; Ekmekci H; Sevinir B; Balci Ekmekci O
Pediatr Hematol Oncol; 2015; 32(7):482-9. PubMed ID: 26271020
[TBL] [Abstract][Full Text] [Related]
18. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
Weycker D; Barron R; Kartashov A; Legg J; Lyman GH
J Oncol Pharm Pract; 2014 Jun; 20(3):190-8. PubMed ID: 23824496
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia].
Rodríguez Z N; Tordecilla C J; Campbell B M; Joannon S P; Rizzardini L C; Soto A V; Verdugo L P
Rev Chilena Infectol; 2005 Sep; 22(3):223-7. PubMed ID: 16077888
[TBL] [Abstract][Full Text] [Related]
20. Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia.
Chindaprasirt J; Wanitpongpun C; Limpawattana P; Thepsuthammarat K; Sripakdee W; Sookprasert A; Wirasorn K
Asian Pac J Cancer Prev; 2013; 14(2):1115-9. PubMed ID: 23621197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
